Understanding factors that contribute to the development of colorectal cancer could point to new targets for treating the disease at earlier stages, when survival rates are highest.

The findings of a new research study increase understanding of the molecular drivers of C. diff infection and point to novel therapeutic strategies aimed at a pathogen that causes about half a million infections in the U.S. each year.

The approach will address “bottlenecks” that slow the traditional antibody discovery process, and it aims to make it possible to generate monoclonal antibody therapies against any target of interest.

Most of the more than 200 species of viruses known to reside in humans remain poorly understood, and new ones are being discovered every few months.

Skaar, who directs the Vanderbilt Institute for Infection, Immunology and Inflammation, is being recognized for “pioneering work at the intersection of nutrition and infectious diseases."

Previous studies suggested that fostamatinib may suppress inflammatory responses triggered by COVID-19 and mitigate ongoing lung injury, decreasing mortality and oxygen requirements.

To reduce your risk of becoming ill and to create a safe environment for our coworkers and patients, a reminder of these essential infection prevention precautions